251. Preparation and preliminary quality evaluation of aspirin/L-glutamate compound pellets.
- Author
-
Xu M, Liu F, Zhou W, He B, and Tan S
- Subjects
- Animals, Chemistry, Pharmaceutical methods, Chemistry, Pharmaceutical standards, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical methods, Drug Evaluation, Preclinical standards, Gastric Mucosa drug effects, Gastrointestinal Tract drug effects, Quality Control, Rats, Rats, Sprague-Dawley, Stomach Ulcer drug therapy, Stomach Ulcer pathology, Tablets, Enteric-Coated, Aspirin administration & dosage, Aspirin chemical synthesis, Aspirin pharmacology, Drug Compounding methods, Drug Compounding standards, Glutamic Acid administration & dosage, Glutamic Acid chemical synthesis, Glutamic Acid pharmacology
- Abstract
L-glutamate is an important component of protein. It can prevent gastrointestinal damage caused by NSAIDs. We constructed two-phase enteric-coated granules of aspirin and L-glutamate compound by extrusion spheronization method and fluidized bed coating. The subliminal effective dose of L-glutamate is 100 mg/kg tested by model of gastric ulcer of rats induced by aspirin and drug administration. HPLC-UV and UV-Vis methods were adopted to determine content and cumulative release of aspirin and L-glutamate as quality analysis method indexes. The prescription and process optimization were carried out with yield, sphericity and dissolution. The two-phase compound granules have good sphericity of 0.93 ± 0.05 (aspirin pellets) and 0.94 ± 0.02 (L-glutamate pellets), content of salicylic acid (0.24 ± 0.03)%, dissolution of aspirin (2.36 ± 0.11)%. Quality evaluation and preliminary stability meet the commercial requirements. The stored environment of compound preparation should be sealed in a cool and dark place., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF